Literature DB >> 32017074

Epigenetic plasticity potentiates a rapid cyclical shift to and from an aggressive cancer phenotype.

Tong Xu1, Hong-Tao Li2, Jenny Wei1, Meng Li3, Tien-Chan Hsieh1, Yi-Tsung Lu1, Ranjani Lakshminarasimhan2, Rong Xu2, Emmanuelle Hodara1, Gareth Morrison1, Hemant Gujar2, Suhn Kyong Rhie4, Kimberly Siegmund5, Gangning Liang2, Amir Goldkorn1.   

Abstract

Highly tumorigenic, drug-resistant cancer stem-like cells drive cancer progression. These aggressive cells can arise repeatedly from bulk tumor cells independently of mutational events, suggesting an epigenetic mechanism. To test this possibility, we studied bladder cancer cells as they cyclically shifted to and from a cancer stem-like phenotype, and we discovered that these two states exhibit distinct DNA methylation and chromatin accessibility. Most differential chromatin accessibility was independent of methylation and affected the expression of driver genes such as E2F3, a cell cycle regulator associated with aggressive bladder cancer. Cancer stem-like cells exhibited increased E2F3 promoter accessibility and increased E2F3 expression that drove cell migration, invasiveness and drug resistance. Epigenetic interference using a DNA methylation inhibitor blocked the transition to a cancer stem-like state and reduced E2F3 expression. Our findings indicate that epigenetic plasticity plays a key role in the transition to and from an aggressive, drug-resistant phenotype.
© 2020 UICC.

Entities:  

Keywords:  zzm321990E2F; cancer plasticity; cancer stem-like cells; chromatin accessibility; drug resistance

Mesh:

Substances:

Year:  2020        PMID: 32017074      PMCID: PMC7448727          DOI: 10.1002/ijc.32904

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  57 in total

1.  Cancer cells cyclically lose and regain drug-resistant highly tumorigenic features characteristic of a cancer stem-like phenotype.

Authors:  Kaijie He; Tong Xu; Amir Goldkorn
Journal:  Mol Cancer Ther       Date:  2011-04-25       Impact factor: 6.261

2.  Nucleosome positioning: an essential component of the enhancer regulatory code?

Authors:  Ahmet Ay; David N Arnosti
Journal:  Curr Biol       Date:  2010-05-11       Impact factor: 10.834

3.  A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations.

Authors:  Sreenath V Sharma; Diana Y Lee; Bihua Li; Margaret P Quinlan; Fumiyuki Takahashi; Shyamala Maheswaran; Ultan McDermott; Nancy Azizian; Lee Zou; Michael A Fischbach; Kwok-Kin Wong; Kathleyn Brandstetter; Ben Wittner; Sridhar Ramaswamy; Marie Classon; Jeff Settleman
Journal:  Cell       Date:  2010-04-02       Impact factor: 41.582

4.  5-azacytidine treatment reorganizes genomic histone modification patterns.

Authors:  Vitalina M Komashko; Peggy J Farnham
Journal:  Epigenetics       Date:  2010-04-01       Impact factor: 4.528

Review 5.  Targeting the cancer epigenome for therapy.

Authors:  Peter A Jones; Jean-Pierre J Issa; Stephen Baylin
Journal:  Nat Rev Genet       Date:  2016-09-15       Impact factor: 53.242

Review 6.  The Rb-E2F transcriptional regulatory pathway in tumor angiogenesis and metastasis.

Authors:  Courtney Schaal; Smitha Pillai; Srikumar P Chellappan
Journal:  Adv Cancer Res       Date:  2014       Impact factor: 6.242

7.  Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.

Authors:  A Gordon Robertson; Jaegil Kim; Hikmat Al-Ahmadie; Joaquim Bellmunt; Guangwu Guo; Andrew D Cherniack; Toshinori Hinoue; Peter W Laird; Katherine A Hoadley; Rehan Akbani; Mauro A A Castro; Ewan A Gibb; Rupa S Kanchi; Dmitry A Gordenin; Sachet A Shukla; Francisco Sanchez-Vega; Donna E Hansel; Bogdan A Czerniak; Victor E Reuter; Xiaoping Su; Benilton de Sa Carvalho; Vinicius S Chagas; Karen L Mungall; Sara Sadeghi; Chandra Sekhar Pedamallu; Yiling Lu; Leszek J Klimczak; Jiexin Zhang; Caleb Choo; Akinyemi I Ojesina; Susan Bullman; Kristen M Leraas; Tara M Lichtenberg; Catherine J Wu; Nicholaus Schultz; Gad Getz; Matthew Meyerson; Gordon B Mills; David J McConkey; John N Weinstein; David J Kwiatkowski; Seth P Lerner
Journal:  Cell       Date:  2017-10-05       Impact factor: 41.582

8.  Role of E2F3 expression in modulating cellular proliferation rate in human bladder and prostate cancer cells.

Authors:  A Y Olsson; A Feber; S Edwards; R Te Poele; I Giddings; S Merson; C S Cooper
Journal:  Oncogene       Date:  2006-08-14       Impact factor: 9.867

9.  Enhancer methylation dynamics contribute to cancer plasticity and patient mortality.

Authors:  Rachel E Bell; Tamar Golan; Danna Sheinboim; Hagar Malcov; David Amar; Avi Salamon; Tamar Liron; Sahar Gelfman; Yankel Gabet; Ron Shamir; Carmit Levy
Journal:  Genome Res       Date:  2016-02-23       Impact factor: 9.043

10.  Low-level processing of Illumina Infinium DNA Methylation BeadArrays.

Authors:  Timothy J Triche; Daniel J Weisenberger; David Van Den Berg; Peter W Laird; Kimberly D Siegmund
Journal:  Nucleic Acids Res       Date:  2013-03-09       Impact factor: 16.971

View more
  7 in total

1.  DNMT and EZH2 inhibitors synergize to activate therapeutic targets in hepatocellular carcinoma.

Authors:  Lian Zhang; Hong-Tao Li; Rachel Shereda; Qianjin Lu; Daniel J Weisenberger; Casey O'Connell; Keigo Machida; Woojin An; Heinz-Josef Lenz; Anthony El-Khoueiry; Peter A Jones; Minmin Liu; Gangning Liang
Journal:  Cancer Lett       Date:  2022-09-08       Impact factor: 9.756

2.  A Novel DNA Methylation Signature as an Independent Prognostic Factor in Muscle-Invasive Bladder Cancer.

Authors:  Zhijie Xu; Hemant Gujar; Guanghou Fu; Hamed Ahmadi; Sumeet Bhanvadia; Daniel J Weisenberger; Baiye Jin; Parkash S Gill; Inderbir Gill; Siamak Daneshmand; Kimberly D Siegmund; Gangning Liang
Journal:  Front Oncol       Date:  2021-02-15       Impact factor: 5.738

3.  Novel Epigenetic Eight-Gene Signature Predictive of Poor Prognosis and MSI-Like Phenotype in Human Metastatic Colorectal Carcinomas.

Authors:  Valentina Condelli; Giovanni Calice; Alessandra Cassano; Michele Basso; Maria Grazia Rodriquenz; Angela Zupa; Francesca Maddalena; Fabiana Crispo; Michele Pietrafesa; Michele Aieta; Alessandro Sgambato; Giampaolo Tortora; Pietro Zoppoli; Matteo Landriscina
Journal:  Cancers (Basel)       Date:  2021-01-05       Impact factor: 6.639

4.  Characterizing DNA methylation signatures and their potential functional roles in Merkel cell carcinoma.

Authors:  Hemant Gujar; Arjun Mehta; Hong-Tao Li; Yvonne C Tsai; Xiangning Qiu; Daniel J Weisenberger; Miriam Galvonas Jasiulionis; Gino K In; Gangning Liang
Journal:  Genome Med       Date:  2021-08-16       Impact factor: 11.117

5.  Role of the WOR1 Promoter of Candida albicans in Opaque Commitment.

Authors:  Thomas P Conway; Kayla Conway; Frank A Boksa; Claude Pujol; Deborah Wessels; David R Soll
Journal:  mBio       Date:  2021-09-07       Impact factor: 7.867

6.  FOXC1 Binds Enhancers and Promotes Cisplatin Resistance in Bladder Cancer.

Authors:  Yi-Tsung Lu; Tong Xu; Maheen Iqbal; Tien-Chan Hsieh; Zhifei Luo; Gangning Liang; Peggy J Farnham; Suhn K Rhie; Amir Goldkorn
Journal:  Cancers (Basel)       Date:  2022-03-28       Impact factor: 6.639

7.  Bladder cancer cells shift rapidly and spontaneously to cisplatin-resistant oxidative phosphorylation that is trackable in real time.

Authors:  Tong Xu; Jason A Junge; Alireza Delfarah; Yi-Tsung Lu; Cosimo Arnesano; Maheen Iqbal; Kevin Delijani; Tien-Chan Hsieh; Emmanuelle Hodara; Hemal H Mehta; Pinchas Cohen; Nicholas A Graham; Scott E Fraser; Amir Goldkorn
Journal:  Sci Rep       Date:  2022-04-01       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.